- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
The amount of FDA draft guidance in play during the past few months has drawn skepticism from the pharmaceutical industry, which has its own thoughts on how best to address the broad scope of the agency’s proposed authority. Jaclyn Jaeger reports.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec.
Annual Membership best value
Subscribe now for $365
Our lowest price ($1 per day) for one year.
In a precedent-setting case, drugmaker Mallinckrodt Pharmaceuticals has agreed to a $35 million settlement with the U.S. federal government for failing to monitor its sales channels for suspicious orders.
At a recent hearing with the CEO of Mylan, the maker of EpiPen, legislators hinted at not only price controls, but an increased scrutiny of executive pay. Joe Mont has more.
The pharmaceutical industry faces fresh regulatory pressure around the world over data integrity issues, reports Jaclyn Jaeger, particularly involving clinical trials.
